Logo image of IMMX

IMMIX BIOPHARMA INC (IMMX) Stock Fundamental Analysis

NASDAQ:IMMX - Nasdaq - US45258H1068 - Common Stock - Currency: USD

1.87  +0.12 (+6.86%)

Fundamental Rating

2

IMMX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. IMMX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMMX has reported negative net income.
In the past year IMMX has reported a negative cash flow from operations.
In the past 5 years IMMX always reported negative net income.
In the past 5 years IMMX always reported negative operating cash flow.
IMMX Yearly Net Income VS EBIT VS OCF VS FCFIMMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

IMMX's Return On Assets of -94.18% is on the low side compared to the rest of the industry. IMMX is outperformed by 74.78% of its industry peers.
IMMX's Return On Equity of -163.11% is on the low side compared to the rest of the industry. IMMX is outperformed by 65.43% of its industry peers.
Industry RankSector Rank
ROA -94.18%
ROE -163.11%
ROIC N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMMX Yearly ROA, ROE, ROICIMMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

IMMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMX Yearly Profit, Operating, Gross MarginsIMMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMMX has more shares outstanding
Compared to 5 years ago, IMMX has more shares outstanding
There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMMX Yearly Shares OutstandingIMMX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IMMX Yearly Total Debt VS Total AssetsIMMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

IMMX has an Altman-Z score of -4.03. This is a bad value and indicates that IMMX is not financially healthy and even has some risk of bankruptcy.
IMMX has a Altman-Z score (-4.03) which is comparable to the rest of the industry.
There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.03
ROIC/WACCN/A
WACCN/A
IMMX Yearly LT Debt VS Equity VS FCFIMMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 2.33 indicates that IMMX has no problem at all paying its short term obligations.
The Current ratio of IMMX (2.33) is worse than 72.84% of its industry peers.
IMMX has a Quick Ratio of 2.33. This indicates that IMMX is financially healthy and has no problem in meeting its short term obligations.
IMMX's Quick ratio of 2.33 is on the low side compared to the rest of the industry. IMMX is outperformed by 70.90% of its industry peers.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.33
IMMX Yearly Current Assets VS Current LiabilitesIMMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

IMMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.42%, which is quite good.
EPS 1Y (TTM)11.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMMX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.46%
EPS Next 2Y2.73%
EPS Next 3Y-4.69%
EPS Next 5Y38.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMMX Yearly Revenue VS EstimatesIMMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 2028 2029 2030 2031 50M 100M 150M
IMMX Yearly EPS VS EstimatesIMMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMMX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMX Price Earnings VS Forward Price EarningsIMMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMX Per share dataIMMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

IMMX's earnings are expected to decrease with -4.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.73%
EPS Next 3Y-4.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMIX BIOPHARMA INC

NASDAQ:IMMX (4/25/2025, 8:15:43 PM)

1.87

+0.12 (+6.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners12.26%
Inst Owner Change-70.06%
Ins Owners28.49%
Ins Owner Change1.09%
Market Cap51.84M
Analysts82.86
Price Target7.14 (281.82%)
Short Float %2.08%
Short Ratio7.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.9%
Min EPS beat(2)-47.06%
Max EPS beat(2)37.25%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-76.92%
EPS NY rev (1m)-13.83%
EPS NY rev (3m)-48.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.91
P/tB 3.91
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.18%
ROE -163.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1020.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.33
Altman-Z -4.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.43%
EPS Next Y14.46%
EPS Next 2Y2.73%
EPS Next 3Y-4.69%
EPS Next 5Y38.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.35%
OCF growth 3YN/A
OCF growth 5YN/A